TITLE:
Factors Associated with Renal Impairment in Patients on Tenofovir for Chronic Hepatitis B in Yaoundé (Cameroon)
AUTHORS:
Antonin Wilson Ndjitoyap Ndam, Sonia Charlsia Ewuo Shu, Mahamat Maimouna, Winnie Bekolo Nga, Isabelle Dang Babagna, Paul Talla, Mathurin Kowo, Firmin Ankouane Andoulo, Gloria Enow Ashuntantang
KEYWORDS:
Chronic Hepatitis B, Tenofovir, Factors Associated, Renal Impairment, Cameroon
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.14 No.1,
January
24,
2024
ABSTRACT: Background: Tenofovir (TFV) is widely used to treat patients with hepatitis B virus (HBV) infection. But kidney abnormalities are the main concern using this drug. Few studies have described the renal impairment due to the TFV in chronic hepatitis B (CHB) in Sub-Saharan Africa. The objective was to evaluate factors associated with renal impairment observed in patients on TFV for CHB. Method: It was a hospital based cross sectional prospective study carried out from June 2023 to July 2023 in Yaoundé (Cameroon) and included any patient treated with TFV for CHB during at least a period of 6 months. For each participant, we collected in the medical report socio-demographic data, clinical data, baseline creatinine, treatment information (type of TFV which was Disoproxil Fumarate (TDF) or Alafenamide (TAF), duration). Then, we collected blood samples to measure serum creatinine and phosphate levels and urine dipstick analysis. Factors associated with renal impairment were assessed with the Odds Ratio. A p value of Results: A total of 60 participants were included. The median age was 44 years [36-55] and median duration of TFV therapy was 17.5 months [11.7-25.7]. The prevalence of reduced eGFR (Conclusion: Kidney function was impaired in some patients receiving TFV for CHB. It should be monitored, particularly after 36 months and for those receiving TDF prodrug.